A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- T-cell Lymphoma
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00322985
- Locations
- π¨π¦
Cancer Care Manitoba, Winnipeg, Manitoba, Canada
π¨π¦Queen Elizabeth II, Health Services Centre, Halifax,, Nova Scotia, Canada
π¨π¦Ottawa Hospital General Campus, Ottawa, Ontario, Canada
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Phase 1
Terminated
- Conditions
- Neuroendocrine TumoursRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 92
- Registration Number
- NCT00323076
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00314470
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00314535
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 5
- Registration Number
- NCT00314522
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Development of Magnetic Resonance (MR) Simulation for Treatment Planning
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-14
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT00314496
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer
Not Applicable
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 16
- Registration Number
- NCT00310479
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00309504
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 72
- Registration Number
- NCT00291304
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Neoplasm MetastasisProstatic NeoplasmsPalliative Care
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT00271687
- Locations
- π¨π¦
Cross Cancer Institute, Edmonton, Alberta, Canada
Β© Copyright 2025. All Rights Reserved by MedPath